Global Cancer Minimal Residual Disease Testing Market Growth 2023-2029

Global Cancer Minimal Residual Disease Testing Market Growth 2023-2029

Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
LPI (LP Information)' newest research report, the “Cancer Minimal Residual Disease Testing Industry Forecast” looks at past sales and reviews total world Cancer Minimal Residual Disease Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Minimal Residual Disease Testing sales for 2023 through 2029. With Cancer Minimal Residual Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Minimal Residual Disease Testing industry.
This Insight Report provides a comprehensive analysis of the global Cancer Minimal Residual Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Minimal Residual Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cancer Minimal Residual Disease Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Minimal Residual Disease Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Minimal Residual Disease Testing.
The global Cancer Minimal Residual Disease Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cancer Minimal Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cancer Minimal Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cancer Minimal Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cancer Minimal Residual Disease Testing players cover Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health and ICON plc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Minimal Residual Disease Testing market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
Segmentation by application
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera, Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cancer Minimal Residual Disease Testing market?
What factors are driving Cancer Minimal Residual Disease Testing market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cancer Minimal Residual Disease Testing market opportunities vary by end market size?
How does Cancer Minimal Residual Disease Testing break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.